UnitedHealth Group shares tumbled in early premarket trading on Monday after Warren Buffett's Berkshire Hathaway revealed it had liquidated its entire position in the health insurance giant. The stock was indicated at $375.06 at 4:00 a.m. EDT, representing a 4.8% decline from Friday's close of $393.85. The selloff adds pressure to a stock that had recently rallied to within striking distance of its 52-week high.
Berkshire's decision to exit UnitedHealth was disclosed in a regulatory filing late Friday, part of a broader first-quarter portfolio reshuffle that also included the sale of smaller positions in Amazon, Visa, and Mastercard. The move comes shortly after Greg Abel's appointment as CEO of Berkshire, signaling a potential shift in the conglomerate's investment strategy. While Berkshire's $288 billion U.S. stock portfolio remains heavily concentrated, the sale of UnitedHealth removes a significant healthcare holding.
The timing of the divestiture is notable, as UnitedHealth had been riding a wave of investor enthusiasm for managed-care stocks. The stock closed Friday up 25.4% over the prior 30 days, just 2.6% below its May 13 high of $404.15. The premarket decline suggests that Berkshire's exit may dampen sentiment, even though the company's fundamentals remain unchanged.
UnitedHealth's recent strength has been fueled by better-than-expected medical cost trends. The company reported first-quarter revenue of $111.7 billion, up 2% year-over-year, with adjusted earnings of $7.23 per share. Management also raised its 2026 adjusted earnings forecast to above $18.25 per share. CEO Stephen Hemsley emphasized the company's commitment to delivering greater value and connectivity in healthcare.
However, caution remains among analysts and executives. CFO Wayne DeVeydt, speaking at the BofA healthcare conference, noted that while Q1 was strong, the company must monitor April and May claims data closely, as many first-quarter claims are paid during this period. If favorable trends persist, DeVeydt said it could be a very strong year. Morningstar analyst Julie Utterback echoed this sentiment, stating it is probably too early to declare victory, while Leerink Partners' Whit Mayo highlighted that the second quarter is typically the test for health insurers.
The broader healthcare sector is also under scrutiny. Major insurers including Cigna, Humana, and Elevance Health all reported first-quarter beats, with several citing better expense control. However, the mild flu season and weather-related delays in care utilization may have artificially boosted early results. Medicare Advantage payment rates remain a headwind, and UnitedHealthcare CEO Tim Noel has indicated that some benefit cuts in 2027 may be necessary to protect margins.
As UnitedHealth heads into Monday's regular trading session, the stock faces a dual narrative: strong earnings momentum on one hand and the exit of a high-profile shareholder on the other. The opening auction will provide the first test of how the market balances these forces. Investors will also watch peers for signs of sustained cost control, as a solid second quarter could reinforce the bull case, while a spike in claims would amplify the impact of Berkshire's disclosure.
